Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy.
Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Spain Polytechnic Hospital La Fe, Bulevar Sur, s/n., 46026, Valencia, Spain, pablooftalmologia@yahoo.es.
Pablo
P
Hernández-Martínez
Rosa
R
Dolz-Marco
Marta
M
Alonso-Plasencia
Rodrigo
R
Abreu-Gonzalez
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D002833:Choroiditis / Q000175:diagnosis / Q000188:drug therapy*; D057915:Drug Substitution; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab